Department of Perioperative Medicine, Division of Anesthesiology, Showa University School of Dentistry, 2-1-1 Kitasenzoku, Ota-ku, Tokyo, 145-8515, Japan.
Department of Pharmacology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Psychopharmacology (Berl). 2018 Sep;235(9):2631-2642. doi: 10.1007/s00213-018-4955-z. Epub 2018 Jun 27.
Tramadol is an analgesic with monoamine reuptake inhibition and μ-opioid receptor activation. Although tramadol has been widely used for treatment of various pain conditions, there is controversy over the risk of abuse potential. We examined the effects of tramadol on the reward system in humans using functional magnetic resonance imaging (fMRI) to assess the potential of tramadol for drug abuse or dependence.
A randomized, double-blind, placebo-controlled, crossover study was conducted for 19 healthy adults under tramadol or placebo. In association with subjective mood questionnaires, monetary incentive delay (MID) task was performed to assess the neural response to reward anticipation during fMRI. Subjective mood measures and blood oxygenation level-dependent (BOLD) signal during gain and loss anticipation were compared between tramadol and placebo.
Tramadol significantly reduced anxiety (Z = - 2.513, p = 0.012) and enhanced vigor (Z = - 2.725, p = 0.006) compared with placebo. By Mood Rating Scale, tramadol provoked contented (Z = - 2.316, p = 0.021), relaxed (Z = - 2.236, p = 0.025), and amicable feelings (Z = - 2.015, p = 0.044) as well as increased alertness (Z = - 1.972, p = 0.049) and contentedness domains (Z = - 2.174, p = 0.030) compared with placebo. Several brain regions including nucleus accumbens (NAc) were activated during gain anticipation in the MID task under both tramadol and placebo. Tramadol increased the %BOLD signal change in NAc at +¥500 cue significantly more than the placebo (Z = - 2.295, p = 0.022).
Tramadol enhances the reward system and thereby may have abuse potential or precipitate drug abuse in human.
曲马多是一种具有单胺再摄取抑制和μ-阿片受体激活作用的镇痛药。尽管曲马多已被广泛用于治疗各种疼痛病症,但关于其滥用潜力仍存在争议。我们使用功能磁共振成像(fMRI)研究曲马多对人类奖励系统的影响,以评估曲马多产生药物滥用或依赖的潜力。
对 19 名健康成年人进行了一项随机、双盲、安慰剂对照、交叉研究,他们接受了曲马多或安慰剂治疗。结合主观情绪问卷,进行金钱激励延迟(MID)任务,以在 fMRI 中评估对奖励预期的神经反应。比较了曲马多和安慰剂治疗时获得和失去预期期间的主观情绪测量和血氧水平依赖(BOLD)信号。
与安慰剂相比,曲马多显著降低了焦虑感(Z=-2.513,p=0.012)并增强了活力感(Z=-2.725,p=0.006)。根据情绪评定量表,曲马多引起了满足感(Z=-2.316,p=0.021)、放松感(Z=-2.236,p=0.025)和友善感(Z=-2.015,p=0.044),以及提高了警觉性(Z=-1.972,p=0.049)和满足感(Z=-2.174,p=0.030)。在 MID 任务中,获得预期时,包括伏隔核(NAc)在内的多个脑区在曲马多和安慰剂下均被激活。曲马多在+¥500 线索时比安慰剂更显著地增加了 NAc 的%BOLD 信号变化(Z=-2.295,p=0.022)。
曲马多增强了奖励系统,因此可能具有滥用潜力或导致人类药物滥用。